(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a dinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.
- 0 Comments
- FY2022